DALLAS, March 13 /PRNewswire/ -- BioMagnetics Diagnostics Corp. (Pink Sheets: BMGP) has been rated Speculative Buy with a price target of $1.42 by Beacon Equity Research Analyst, Lisa Springer, CFA.
The full report is available at http://www.BeaconEquity.com.
Anyone interested in receiving alerts regarding BioMagnetics Diagnostics research should email email@example.com with "BMGP" in the subject line.
In the report, the analyst writes, "Biomagnetics Diagnostics Corp. (BMGP) is a biotechnology company engaged in the discovery, development and marketing of new and innovative diagnostic equipment and immunoassays. The Company, through its wholly owned subsidiary, Bio-Spectrum Technologies, Inc., develops and patents potentially revolutionary diagnostic technologies.
"BMGP's flagship product, the High Throughput Screening-Magnetic Testing Platform (HTS-MTP) diagnostic system, is designed to detect any pathogen -- viral or bacterial -- using any body fluid as the testing median. It is the only system that measures viral load concomitantly with detection. Moreover, using the HTS-MTP system, multiple tests can be performed in one assay in a matter of minutes; that is several hundred percent more assays per hour than existing technologies at a fraction of the cost."
Beacon Equity Research Disclosure
The analysts contributing to this report do not hold any shares of
BioMagnetics (BMGP). Additionally the analysts contributing to this report
certify that the views expressed herein accurately reflect the analysts'
personal views as to the subject securities and issuers. The analyst(s)
writing this report recognize and aspire to all of the CFA Institute
Guidelines for Independent Research. Beacon Equity Research ("Beacon")
certifies that no part of the analysts' compensation was, is, or will be,
directly or indirectly, rel
Copyright©2008 PR Newswire.
All rights reserved